Transgene SA (TNG.PA)
- Previous Close
1.2800 - Open
1.3000 - Bid --
- Ask --
- Day's Range
1.1840 - 1.3000 - 52 Week Range
1.0300 - 2.5500 - Volume
74,243 - Avg. Volume
38,426 - Market Cap (intraday)
122.032M - Beta (5Y Monthly) 0.72
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2200 - Earnings Date May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.50
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Merck & Co, Sanofi, BioInvent, and Randox. Transgene SA was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
www.transgene.frRecent News: TNG.PA
Performance Overview: TNG.PA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TNG.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TNG.PA
Valuation Measures
Market Cap
122.03M
Enterprise Value
107.62M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
102.80
Price/Book (mrq)
7.82
Enterprise Value/Revenue
90.90
Enterprise Value/EBITDA
-5.23
Financial Highlights
Profitability and Income Statement
Profit Margin
-282.63%
Return on Assets (ttm)
-33.64%
Return on Equity (ttm)
-83.54%
Revenue (ttm)
7.9M
Net Income Avi to Common (ttm)
-22.33M
Diluted EPS (ttm)
-0.2200
Balance Sheet and Cash Flow
Total Cash (mrq)
15.67M
Total Debt/Equity (mrq)
110.78%
Levered Free Cash Flow (ttm)
-5.41M
Research Analysis: TNG.PA
Company Insights: TNG.PA
TNG.PA does not have Company Insights